Terry Mark A
Trans Am Ophthalmol Soc. 2007;105:530-63.
To evaluate the clinical outcome of small-incision, deep lamellar endothelial keratoplasty (DLEK) for the treatment of endothelial dysfunction.
A prospective series of 79 eyes that underwent DLEK by a single surgeon was evaluated. Best spectacle-corrected visual acuity (BSCVA), refractive astigmatism, and central endothelial cell density (ECD) were measured preoperatively and at 6, 12, and 24 months.
Data was available on 78 eyes (99%) at 6 months, 77 eyes (97%) at 1 year, and 79 eyes (100%) at 2 years. Mean BSCVA preoperatively of 20/71 improved to 20/42 by 6 months and remained stable. Eliminating eyes with known retinal disease, BSCVA of 20/40 or better was present in 60% (40 of 67) of eyes at 6 months, 74% (49 of 66) of eyes at 1 year, and 79% (53 of 68) of eyes at 2 years. Refractive astigmatism preoperatively was .91 +/-.78 diopters and was unchanged by surgery over time with results at 6 months of 1.11 +/-.76 (P = .052, power = .43), 1 year 1.04 +/-.80 (P =.287, power = .06), and 2 years 1.10 +/-.70 (P =.467, power = .22). The mean donor ECD preoperatively was 2819 +/- 225 (2389 to 3385) cells/mm(2), and this decreased by 26% at 6 months (2095 +/- 380) (1097 to 2920) (P = .0001; 95% confidence interval [CI] = 643-809), 3% fewer at 1 year (2009 +/- 393) (612 to 2723) (P = .054, power = .5), and 17% fewer at 2 years (1536 +/- 547) (500 to 2546) (P < .001, 95% CI = 368-585). Complications included one primary graft failure and 4 dislocations into the anterior chamber.
DLEK provides improved vision and minimal refractive astigmatic change, but progressive ECD decrease over time is of concern.
评估小切口深层板层内皮角膜移植术(DLEK)治疗内皮功能障碍的临床效果。
对由单一外科医生实施DLEK手术的79只眼进行前瞻性研究。术前及术后6个月、12个月和24个月测量最佳矫正视力(BSCVA)、屈光性散光和中央内皮细胞密度(ECD)。
6个月时78只眼(99%)、1年时77只眼(97%)、2年时79只眼(100%)有可用数据。术前平均BSCVA为20/71,6个月时提高到20/42并保持稳定。排除已知视网膜疾病的眼后,6个月时60%(67只眼中的40只)、1年时74%(66只眼中的49只)、2年时79%(68只眼中的53只)的眼BSCVA达到20/40或更好。术前屈光性散光为0.91±0.78屈光度,术后随时间无变化,6个月时为1.11±0.76(P = 0.052,检验效能 = 0.43),1年时为1.04±0.80(P = 0.287,检验效能 = 0.06),2年时为1.10±0.70(P = 0.467,检验效能 = 0.22)。术前供体ECD平均为2819±225(2389至3385)个细胞/mm²,6个月时下降26%(2095±380)(1097至2920)(P = 0.0001;95%可信区间[CI] = 643 - 809),1年时少3%(2009±393)(612至2723)(P = 0.054,检验效能 = 0.5),2年时少17%(1536±547)(500至2546)(P < 0.001,95% CI = 368 - 585)。并发症包括1例原发性移植失败和4例移植片脱入前房。
DLEK可改善视力且屈光性散光变化最小,但随时间推移内皮细胞密度逐渐下降令人担忧。